Predictive factors of stent patency in iliofemoral venous diseases in a multicenter cohort study

Autor: Olivier Espitia, Frédéric Douane, Jeanne Hersant, Fabrice Abbadie, Jonathan Sobocinski, Jean-François Heautot, Annaïg Miossec, François-Xavier Lapébie, Olivier Hartung, Francine Thouveny, Arthur David, Samir Henni, Alexis F. Guédon, Agathe de Préville, Hervé Rousseau, Paul Revel-Mouroz, Béatrice Guyomarch, Guillaume Mahé, Giovanni Gautier, Blandine Maurel
Přispěvatelé: Centre hospitalier universitaire de Nantes (CHU Nantes), Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM), Médicaments et biomatériaux à libération contrôlée: mécanismes et optimisation - Advanced Drug Delivery Systems - U 1008 (MBLC - ADDS), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Service de radiologie et imagerie médicale [Rennes] = Radiology [Rennes], CHU Pontchaillou [Rennes], Service de Médecine Vasculaire [CHU Toulouse], Pôle Cardiovasculaire et Métabolique [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), CHU Marseille
Jazyk: angličtina
Rok vydání: 2023
Předmět:
Zdroj: European Journal of Vascular and Endovascular Surgery
European Journal of Vascular and Endovascular Surgery, 2023, European Journal of Vascular and Endovascular Surgery, ⟨10.1016/j.ejvs.2023.01.005⟩
ISSN: 1078-5884
DOI: 10.1016/j.ejvs.2023.01.005⟩
Popis: International audience; ObjectiveThis study assessed primary stent patency predictive factors in three groups of patients with history of lower limb (LL) vein thrombosis: non-thrombotic iliac vein lesion (NIVL), acute deep vein thrombosis (aDVT), and post-thrombotic syndrome (PTS).MethodsConsecutive patients from January 2014 to December 2020 with history of LL vein stenting from seven hospitals were included. All patients received an iliac or common femoral venous stent and had at least a six month follow up available with stent imaging. Anticoagulant and antiplatelet therapy strategies employed after venous stenting are reported and compared between groups.ResultsThis study included 377 patients: 134 NIVL, 55 aDVT, and 188 PTS. Primary patency was statistically significantly higher in the NIVL group (99.3%) compared with the PTS group (68.6%) (p < .001) and the aDVT group (83.6%) (p = .002). PTS patients received a statistically significantly greater number of stents (p < .001) and had more stents below the inguinal ligament (p < .001). Median follow up was 28.8 months (IQR 16, 47). Discontinuation of antiplatelet therapy at the last assessment was 83.6% for NIVL, 100% for aDVT, and 95.7% for the PTS group (p < .001). Discontinuation of anticoagulation therapy at the last assessment was 93.2% for NIVL, 25.0% for aDVT, and 70.3% for the PTS group (p < .001). The only predictor of worse primary patency in the aDVT group was long term anticoagulation before stenting.ConclusionPatients with NIVL have better primary patency after venous stenting than patients with venous thrombotic disorders. Long term anticoagulation before stenting was the only factor associated with poorer primary patency in patients with aDVT.
Databáze: OpenAIRE
Externí odkaz: